Nuclear factor IA is expressed in astrocytomas and is associated with improved survival
Abstract
Nuclear factor IA (NFIA) is a transcription factor that specifies glial cell identity and promotes astrocyte differentiation during embryonic development. Its expression and function in gliomas are not known. Here, we examined NFIA protein expression in gliomas and its association with clinical outcome in pediatric malignant astrocytomas. We analyzed expression of NFIA by immunohistochemistry in 88 existing glioma specimens from Childrens Hospital Los Angeles and the University of Southern California. Association between NFIA expression and progression-free survival (PFS) was examined in high-grade astrocytomas for which clinical data were available (n = 23, all children). NFIA was highly expressed in astrocytomas of all grades, but only in a minority of cells in oligodendroglial tumors. NFIA was expressed on a higher percentage of tumor cells in low-grade astrocytomas (91 ± 5% and 77 ± 14% in World Health Organization [WHO] I and II, respectively) compared with high-grade astrocytomas (48 ± 18% and 37 ± 16% in WHO III and IV, respectively; P < .001, low- vs high-grade astrocytomas). There was a significant association between NFIA expression and PFS in children with astrocytoma WHO grade III or IV (Cox regression P = .019; logrank trend test for NFIA tertiles P = .0040 and NFIA quartiles P = .014). The association was not consistently significant in this small series of patients after adjustment was made for WHO grade III or IV. This is the first study to demonstrate expression of NFIA protein in astrocytomas and its association with grades of astrocytoma and PFS, suggesting that NFIA may play a role in astrocytoma biology.
Additional Information
© The Author(s) 2010. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. Received February 2, 2009; Accepted March 3, 2009. Advance Access originally published online on January 25, 2010. We thank Dr. Jonathan Finlay for critical reading of the manuscript and helpful suggestions, Lingyun Ji for statistical analysis and the helpful discussions, and Chelsea Seidenglanz for assistance in quantification of immune-histochemical analysis. This work was supported by NIH NICHD grant K12-HD052951, the Children's Cancer Research Fund, a Childrens Hospital Los Angeles Academic Career Development Award, and a Hyundai Research Scholar Award (H.-R.S.). The work was also supported in part by the Nautica Malibu Triathlon Fund, and the Bogart Pediatric Cancer Research Program (A.E.-E.).Attached Files
Published - Song2010p7367Neuro-Oncology.pdf
Files
Name | Size | Download all |
---|---|---|
md5:b62d52579f41c7d192ab5290db0719bb
|
1.7 MB | Preview Download |
Additional details
- PMCID
- PMC2940580
- Eprint ID
- 18642
- Resolver ID
- CaltechAUTHORS:20100610-132108890
- K12-HD052954
- NIH
- Children's Cancer Research Fund
- Childrens Hospital Los Angeles
- Hyundai Research
- Nautica Malibu Triathlon Fund
- Bogart Pediatric Cancer Research Program
- Created
-
2010-07-15Created from EPrint's datestamp field
- Updated
-
2021-11-08Created from EPrint's last_modified field